Brought to you by

Schering-Plough and Neurogen develop neuropsychiatric drugs
16 Mar 2000
Executive Summary
Schering-Plough and Neurogen entered into a strategic alliance to develop and market drugs to treat neuropsychiatric disorders, including schizophrenia. The deal is potentially worth $70 million to Neurogen over the next five years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com